STOCK TITAN

SOPHiA GENETICS (SOPH) CTO receives new option and RSU equity awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma received new equity awards as part of his compensation. He was granted options to buy 119,760 ordinary shares at an exercise price of $5.04 per share, vesting 25% on April 2, 2027 and monthly through April 2, 2030. He also received 82,136 restricted stock units, with 25% vesting on April 2, 2027 and the remaining 75% in equal quarterly installments through April 2, 2030. These are awards from the company, not open-market purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Verma Abhimanyu
Role Chief Technology Officer
Type Security Shares Price Value
Grant/Award Share Option (Right to Buy) 119,760 $0.00 --
Grant/Award Ordinary Shares 82,136 $0.00 --
Holdings After Transaction: Share Option (Right to Buy) — 119,760 shares (Direct); Ordinary Shares — 82,136 shares (Direct)
Footnotes (1)
  1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Option grant size 119,760 shares Share options granted on 2026-04-02
Option exercise price $5.04 per share Conversion or exercise price for granted options
RSU grant size 82,136 units Restricted stock units representing ordinary shares
Option expiration April 2, 2036 Expiration date of the option grant
Initial vesting date April 2, 2027 25% of both RSUs and options vest on this date
RSU vesting end April 2, 2030 Remaining 75% of RSUs vest quarterly through this date
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."
2021 Equity Incentive Plan financial
"RSU grant made under the Issuer's 2021 Equity Incentive Plan."
share option financial
"The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027"
vesting financial
"subject to the Reporting Person's continued service with the Issuer through each applicable vesting date."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"conversion_or_exercise_price": "5.0400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Verma Abhimanyu

(Last)(First)(Middle)
C/O SOPHIA GENETICS SA
LA PIECE 12

(Street)
ROLLE1180

(City)(State)(Zip)

SWITZERLAND

(Country)
2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Technology Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares04/02/2026A82,136(1)A$082,136D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (Right to Buy)$5.0404/02/2026A119,760 (2)04/02/2036Ordinary Shares119,760$0119,760D
Explanation of Responses:
1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
2. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Remarks:
/s/ Elimara Brunetto as Attorney-in-fact for Abhimanyu Verma04/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did SOPH Chief Technology Officer Abhimanyu Verma report?

Abhimanyu Verma reported receiving equity awards, not open-market trades. He was granted options on 119,760 ordinary shares at $5.04 per share and 82,136 restricted stock units, both subject to multi-year vesting schedules tied to his continued service with SOPHiA GENETICS SA.

How many SOPH options were granted to the CTO and at what exercise price?

The CTO received options covering 119,760 ordinary shares with a $5.04 exercise price. These options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030, aligning his long-term incentives with SOPHiA GENETICS SA’s future performance and retention.

What are the terms of the 82,136 SOPH restricted stock units granted?

The filing shows a grant of 82,136 restricted stock units to the CTO. Each unit represents a right to receive one ordinary share, with 25% vesting on April 2, 2027 and the remaining 75% vesting in equal quarterly installments through April 2, 2030, contingent on continued service.

Are the SOPH equity awards to the CTO immediate shares or subject to vesting?

The equity awards are subject to vesting conditions. Options on 119,760 shares vest over time starting April 2, 2027, as do 82,136 restricted stock units. Vesting is contingent on the CTO’s continued service with SOPHiA GENETICS SA through each scheduled vesting date.

Did the SOPH CTO buy or sell any shares on the market in this Form 4?

No market purchases or sales are reported. The Form 4 records compensation-related grants: stock options and restricted stock units awarded at no cash cost per share, with specified vesting schedules. They increase his potential future equity ownership rather than reflecting open-market trading activity.